Floatz logo

Cytokine-Treated Veto Cells

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

M.D. Anderson Cancer CenterCell therapyPhase 1/2Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
65/ 100

Competitive context

211 Active assets in the Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Weill Medical College of Cornell University
Phase 2BBB
Apg-2575
Henan Cancer Hospital
Phase 3BBB
CHLORAMBUCIL
Ascentage Pharma Group Inc.
Phase 4BBB
PREDNISONE TABLETS
AstraZeneca
Phase 3BBB
Irinotecan
IGM Biosciences, Inc.
Phase 2BBB

View all 50 →

Same molecule, other indications

Cytokine-Treated Veto Cells is also rated in:

bone marrow failure syndromeDormant
CCC
Indicative ·
48 / 100
View asset →
Aplastic AnemiaDormant
CCC
Indicative ·
48 / 100
View asset →
chronic myeloid leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →